Mucosal healing in inflammatory bowel disease: where do we stand?
The definition of remission in Crohn's disease and ulcerative colitis has evolved to include mucosal healing as a measure of treatment efficacy. Randomized, controlled trials have demonstrated mucosal healing is attainable with the current arsenal of therapies available to treat inflammatory bowel disease. Mucosal healing has been shown to reduce the likelihood of clinical relapse, reduce the risk of future surgeries, and reduce hospitalizations. This review focuses on the latest studies addressing clinical outcomes of mucosal healing in the clinical trial and practice setting.
Ha
Christina
C
Division of Gastroenterology and Hepatology, The Johns Hopkins School of Medicine, Baltimore, MD 21287, USA. christina.ha@jhmi.edu
Kornbluth
Asher
A
D000068879:Adalimumab; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D003093:Colitis, Ulcerative / Q000188:drug therapy / Q000473:pathology*; D003424:Crohn Disease / Q000188:drug therapy / Q000473:pathology*; D016099:Endoscopy, Gastrointestinal; D005243:Feces / Q000737:chemistry; D006801:Humans; D000069285:Infliximab; D007413:Intestinal Mucosa / Q000473:pathology*; D007781:Lactoferrin / Q000008:administration & dosage; D039841:Leukocyte L1 Antigen Complex / Q000008:administration & dosage
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D039841:Leukocyte L1 Antigen Complex; D000069285:Infliximab; D007781:Lactoferrin; D000068879:Adalimumab